SubQ vs. IM Testosterone Injections: What the Actual Trial Data Shows

Subcutaneous (SubQ) versus intramuscular (IM) testosterone injection gets debated constantly in TRT communities, often as if it's an open question with no real data behind it. It isn't — there are genuine clinical trials directly comparing the two, and they answer the practical questions (does it work as well, is it as safe, does it hurt less) with real numbers rather than opinion. What SubQ and IM Actually Are IM injection delivers testosterone into muscle tissue, which has a rich blood supply and has historically been the default route for oil-based testosterone esters. SubQ injection delivers the same testosterone ester into the fat layer just beneath the skin, using a shorter, thinner needle. The core question worth answering with actual data: does injecting into fat instead of muscle change how well the treatment actually works or how safe it is? Does SubQ Actually Achieve Normal Testosterone Levels? According to PubMed, a Phase II dose-finding study directly tested subcutaneous testosterone enanthate at 50 mg and 100 mg weekly doses against a reference group maintained on standard 200 mg intramuscular testosterone enanthate. Both subcutaneous doses restored normal serum testosterone levels within the standard dosing interval, with dose-proportional pharmacokinetics and low variability relative to the IM reference group. Mean steady-state concentrations reached 422.4 ng/dL and 895.5 ng/dL for the 50 mg and 100 mg subcutaneous arms, respectively ([Kaminetsky, Jaffe & Swerdloff, Sexual Medicine, 2015, PMID: 26797061](https://doi.org/10.1002/sm2.80)). This is a direct, head-to-head answer to the "does it actually work as well" question: yes, subcutaneous dosing restored normal testosterone levels with pharmacokinetics the researchers described as comparable to the intramuscular route, not a compromised alternative to it. What the Real Safety Data Shows According to PubMed, a follow-up Phase III study following 133 men for 26 weeks on a subcutaneous testosterone enanthate auto-injector gives genuinely specific safety numbers rather than general reassurance. Adverse drug reactions occurred in 25.6% of patients, with the most common being: increased hematocrit to 52% or higher in 7.5% of patients, injection-site hemorrhage in 4.5%, injection-site bruising in 3.0%, and elevated PSA in 3.0%. Blood pressure increased modestly (systolic up about 3.4 mmHg by week 26), and — notably, given the pattern covered in our dedicated hematocrit article — all measured lipid fractions were actually below baseline by week 26, not worse ([Gittelman, Jaffe & Kaminetsky, Journal of Sexual Medicine, 2019, PMID: 31551193](https://doi.org/10.1016/j.jsxm.2019.08.013)). The hematocrit elevation rate here (7.5% reaching ≥52%) is a genuinely useful real-world data point for anyone weighing SubQ specifically against the erythrocytosis risk discussed elsewhere on this site — it's a real, quantified, monitorable rate, not an unknown. The Pain Question, Answered With an Actual Number This is the detail most casual comparisons skip, and it's a genuinely striking result. In the same 26-week safety study, researchers assessed pain across 965 total injections administered by the study's patients. The result: mild pain was reported following exactly one injection out of 965. That's not a typo-level anecdote — it's a systematically tracked safety outcome across a real, sizeable patient population, and it points strongly toward subcutaneous injection being genuinely well-tolerated from a pain standpoint, consistent with the smaller-gauge, shorter needle typically used for this route compared to the longer needle IM injection requires to reach muscle tissue. Why the Two Routes Feel Different in Practice Beyond the trial data, a few practical, mechanism-level differences explain why people report different day-to-day experiences with each route. IM injection reaches a tissue bed with faster local blood flow, which some users associate with a more pronounced peak-and-trough sensation across the injection cycle. SubQ injection into fat tissue tends to release more gradually, which is part of the proposed rationale for why some clinicians favor more frequent, smaller subcutaneous doses over less frequent, larger intramuscular ones — steadier levels with smaller peaks, similar in principle to the injection-frequency discussion covered in our articles on hematocrit and estrogen management. It's worth being clear that this is a reasonable pharmacological rationale rather than something the two trials above directly measured against each other in a single head-to-head design — both studies compared subcutaneous dosing against an intramuscular reference standard rather than running a formal peak-trough comparison between the exact same patients on both routes. So Which One Is Actually Better? Based on the real data above, this is genuinely closer to a preference question than a clear medical superiority question — and it's worth saying that plainly rather than manufacturing a winner. Subcutaneous dosing achieves normal testosterone levels with pharmacokinetics the actual trial data describes as comparable to intramuscular dosing. Its measured safety profile (hematocrit, blood pressure, lipids) looks reasonable and is now genuinely quantified rather than assumed. And its pain profile, based on real injection-level data, appears favorable — a legitimate, practical advantage for anyone who finds needles unpleasant or self-injects regularly. Where a genuine, non-preference-based case for one route over the other might still apply: someone needing to hit a very specific trough target with minimal week-to-week variability might have reasons (in consultation with their physician) to prefer one dosing pattern's pharmacokinetic profile over the other. Someone with a strong needle-length aversion has a real, practical reason to prefer the shorter subcutaneous needle. But "one route is medically superior to the other for most patients" isn't what the actual comparative data supports — both appear to be legitimate, well-studied ways to achieve the same therapeutic goal. The Bottom Line SubQ and IM testosterone injection aren't a case of one being an unproven shortcut and the other being the only "real" option — both have genuine trial data behind them, and subcutaneous dosing specifically has been shown to restore normal testosterone levels with a quantified, reasonable safety profile and notably low reported pain across nearly a thousand tracked injections. For most people without a specific clinical reason to prefer one pharmacokinetic profile over the other, this comes down to genuine personal preference — needle comfort, injection frequency, and site rotation convenience — rather than one route being demonstrably better than the other.